Adlai Nortye Reports H1 2026 Results, Pipeline Advances Across Pan-RAS Programs
ANL has more than doubled off its 52-week low of $0.879.
Summary
Adlai Nortye reported unaudited first half 2026 financial results alongside a broad pipeline update. The company confirmed enrollment is ongoing in both QD and QW arms of the global Phase I trial for pan-RAS(ON) inhibitor AN9025, with initial dose escalation data expected in H1 2027. AN4035, a first-in-class pan-RAS(ON) ADC, received HREC approval in Australia and is on track to dose its first patient in H2 2026. The company also announced the appointment of two leading medical oncologists to its Scientific Advisory Board and the de-prioritization of AN4005 monotherapy development. This follows the HREC approval for AN4035 reported on August 3, 2026, and adds financial results plus multiple pipeline milestones. The update provides a comprehensive view of the company's clinical progress and strategic direction, with multiple data readouts expected in 2027.
At the time of this announcement, ANL was trading at $13.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $514.4M. The 52-week trading range was $0.88 to $17.25. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.